Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,078 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renal Transplantation Clear all
Not listed Phase 4 Interventional

Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients

NCT00999258
View directory record Official record
Conditions
Glomerular Filtration Rate, Chronic Allograft Nephropathy
Interventions
sirolimus
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2009 · Synced Sep 9, 2026, 2:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

NCT00415584
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Hypercalcemia
Interventions
Cinacalcet HCl
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 9, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

NCT01820572
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Belatacept, Tacrolimus, Cyclosporine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 9, 2026, 2:15 PM EDT
No Longer Available No phase listed Expanded access

Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)

NCT02051673
View directory record Official record
Conditions
Renal Failure
Interventions
Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 9, 2026, 2:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function

NCT06091995
View directory record Official record
Conditions
Use of Belatacept in Kidney Transplant Patients
Interventions
impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)
Behavioral
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 9, 2026, 2:15 PM EDT
Completed Not applicable Interventional Results available

Increasing Activity Post-Kidney Transplant With SystemCHANGE

NCT03191630
View directory record Official record
Conditions
Kidney Transplant; Complications, Physical Activity, Cardiorenal; Change, Cardiovascular Diseases
Interventions
Fitbit (Control), SystemCHANGE and Fitbit (Intervention)
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 9, 2026, 2:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant

NCT01106027
View directory record Official record
Conditions
Kidney Transplant
Interventions
Eculizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 9, 2026, 2:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Remote Ischemic Preconditioning Living Donor Renal Transplant Protocol

NCT03084666
View directory record Official record
Conditions
Renal Disease
Interventions
Zimmer ATS tourniquet system
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 9, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00079222
View directory record Official record
Conditions
Cancer
Interventions
itraconazole, voriconazole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 9, 2026, 2:15 PM EDT
Withdrawn Not applicable Interventional

Transversus Abdominis Plane (TAP) Block After Kidney Transplantation

NCT01496729
View directory record Official record
Conditions
Transplantation, Kidney
Interventions
Transversus abdominis plane (TAP) block, Sham TAP block with normal saline
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Sep 9, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

NCT01147302
View directory record Official record
Conditions
Graft Rejection
Interventions
Placebo, C1 Esterase Inhibitor (Human)
Biological
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 9, 2026, 2:15 PM EDT
Recruiting Phase 4 Interventional

Empagliflozin Treatment in Kidney Transplant Recipients

NCT06013865
View directory record Official record
Conditions
Kidney Transplant, Chronic Kidney Disease
Interventions
Empagliflozin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 9, 2026, 2:15 PM EDT
Suspended Phase 1 Interventional

Islet Allotransplantation in Type 1 Diabetes

NCT01705899
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Human Pancreatic Islets
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2033
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 9, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation

NCT00302627
View directory record Official record
Conditions
Transplant Bone Disease
Interventions
Pamidronate, vitamin D, Calcium Carbonate
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 9, 2026, 2:15 PM EDT
Completed Phase 4 Interventional Results available

Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

NCT04087720
View directory record Official record
Conditions
Uncontrolled Gout, Kidney Transplant
Interventions
Pegloticase
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 9, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II

NCT02003469
View directory record Official record
Conditions
Hypertension
Interventions
Ambulatory Blood Pressure Monitoring
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 9, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

NCT00533442
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Rapamycin, Mycophenolate Mofetil, Tacrolimus, Steroids
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 9, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Enhancing Kidney Donation Through Live Organ Video Educated Donors (LOVED) Study Phase

NCT03599102
View directory record Official record
Conditions
Kidney Transplantation
Interventions
LOVED Intervention
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 9, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

NCT05921903
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA Investigational Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Chicago, Illinois • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 9, 2026, 2:15 PM EDT
Active, not recruiting Phase 4 Interventional

Immunogenicity of HPV Vaccine in Transplant Recipients.

NCT05557370
View directory record Official record
Conditions
Chronic Kidney Diseases, Kidney Transplant
Interventions
Human Papilloma Virus vaccine (GARDASIL 9)
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 9, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Islet Transplantation for Patients With Type 1 Diabetes

NCT00073281
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet transplantation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Sep 9, 2026, 2:15 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

NCT05525507
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Conditioning and Stem cell infusion
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 9, 2026, 2:15 PM EDT
Completed No phase listed Observational

Urinary Kidney Injury Molecule-1 (KIM-1) Excretion As Biomarker for Injury in Kidney Transplant Recipients

NCT00805571
View directory record Official record
Conditions
Kidney Transplant Dysfunction
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Sep 9, 2026, 2:15 PM EDT
Withdrawn Not applicable Interventional

Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients

NCT01612299
View directory record Official record
Conditions
Renal Transplant
Interventions
Zortress® /Everolimus
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced Sep 9, 2026, 2:15 PM EDT